Filing Flows › CytomX Therapeutics (CTMX) › Q2 2026 › vs Q1 2026
CytomX Therapeutics (CTMX) Q2 2026 vs Q1 2026 (quarter over quarter)
CytomX Therapeutics's revenue fell $8.8M (-86%) from $10.3M in Q1 2026 to $1.4M in Q2 2026.
CytomX Therapeutics, Q2 2026: revenue $1.4M (-92% year over year), net loss $20.7M, operating cash flow −$18.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.4M | $10.3M | −$8.8M | -86% |
| Other income, net | $3.2M | $1.5M | $1.7M | +114% |
| Net loss | $20.7M | $18.2M | $2.4M | +13% |
| Costs & expenses | $25.3M | $30.0M | −$4.7M | -16% |
| Operating costs | $25.2M | $29.9M | −$4.7M | -16% |
| Income tax | $60K | $59K | $1K | +2% |
| Research & development | $17.6M | $19.2M | −$1.6M | -9% |
| General & admin | $7.6M | $10.7M | −$3.1M | -29% |
| Operating cash sources | $20.7M | $18.2M | $2.4M | +13% |
| Share-based compensation | $2.6M | $4.7M | −$2.1M | -45% |
| Working capital & other | $21K | −$12.0M | $12.0M | — |
| Cash used in operations | $18.1M | $25.5M | −$7.5M | -29% |
| Net loss absorbed | $20.7M | $18.2M | $2.4M | +13% |
Questions
How much did CytomX Therapeutics's revenue grow quarter over quarter in Q2 2026?
CytomX Therapeutics's revenue fell $8.8M (-86%) from $10.3M in Q1 2026 to $1.4M in Q2 2026.